Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

M-FEBUXOSTAT 80 MG

FEBUXOSTAT (FEBUXOSTAT HEMIHYDRATE) : 80 MG · DIN 02549425 · MANTRA PHARMA INC

Health Canada status: MARKETED

What is M-FEBUXOSTAT?

M-FEBUXOSTAT 80 MG contains FEBUXOSTAT (FEBUXOSTAT HEMIHYDRATE) : 80 MG. It is listed in the Health Canada Drug Product Database under DIN 02549425, held by MANTRA PHARMA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 25-Apr-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

What is M-FEBUXOSTAT used for?

To lower serum uric acid levels in patients with gout who have an inadequate response or intolerance to allopurinol, or for whom treatment with allopurinol is inappropriate.

Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.

Product details and regulatory record

DIN02549425
Brand nameM-FEBUXOSTAT
Generic / active ingredientFEBUXOSTAT (FEBUXOSTAT HEMIHYDRATE) : 80 MG
ManufacturerMANTRA PHARMA INC
Strength80 MG
Dosage formTABLET
Route of administrationORAL
SchedulePrescription
ATC codeM04AA03 FEBUXOSTAT
BiosimilarNo
Health Canada statusMARKETED
Status date25-Apr-2025

How is it administered?

Recommended for patients with inadequate response/intolerance to allopurinol. Treatment should not start until acute gout attack subsides. Flare prophylaxis with NSAIDs or colchicine recommended.

Included because it drives pack selection and wastage. Consult the monograph.

How is it stored and handled?

Not explicitly detailed in the provided text (refers to Storage and Stability section).

How is it supplied?

Not explicitly detailed in the provided text (refers to Dosage Forms, Composition and Packaging section).

Contraindications

Contraindicated in patients being treated with azathioprine or mercaptopurine; history of hypersensitivity to febuxostat or any other ingredient in the formulation.

Warnings and precautions

Serious Warning: Higher rate of CV death in patients with established CV disease. Not recommended in patients with ischemic heart disease or congestive heart failure. Risk of liver injury.

What can be used instead?

Other Canadian products sharing ATC code M04AA03 FEBUXOSTAT. 6 of 7 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.

ProductStrengthFormManufacturerHealth Canada statusDIN
AURO-FEBUXOSTAT80 MGTABLETAURO PHARMA INCMARKETEDDIN 02533243
FEBUXOSTAT80 MGTABLETSANIS HEALTH INCMARKETEDDIN 02539837
JAMP FEBUXOSTAT80 MGTABLETJAMP PHARMA CORPORATIONMARKETEDDIN 02490870
MAR-FEBUXOSTAT80 MGTABLETMARCAN PHARMACEUTICALS INCMARKETEDDIN 02473607
TEVA-FEBUXOSTAT80 MGTABLETTEVA CANADA LIMITEDMARKETEDDIN 02466198
ULORIC80 MGTABLETTAKEDA CANADA INCCANCELLED POST MARKETDIN 02357380

Who else supplies FEBUXOSTAT worldwide?

Nexara tracks national medicine registries and published price lists across multiple markets. FEBUXOSTAT appears in 164 registered pack listings across 13 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.

Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.

How can I get it?

Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.

Request a quote for M-FEBUXOSTAT

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Health Canada Drug Product Database (DPD), DIN 02549425. Last reviewed 2026-09-10. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.